Impact BioMedical Inc. IBO
AMEX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -57.14% | 0.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -57.14% | 0.00% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -71.43% | 101.69% | |||
| SG&A Expenses | -85.41% | 590.18% | |||
| Depreciation & Amortization | -0.35% | -0.35% | |||
| Other Operating Expenses | 0.00% | -6.94% | |||
| Total Operating Expenses | -69.29% | 97.08% | |||
| Operating Income | 69.33% | -97.67% | |||
| Income Before Tax | 69.35% | -186.03% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 69.35% | -143.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 133.33% | -130.00% | |||
| Net Income | 69.44% | -143.60% | |||
| EBIT | 69.33% | -97.67% | |||
| EBITDA | 79.14% | -129.82% | |||
| EPS Basic | 69.45% | -136.32% | |||
| Normalized Basic EPS | 69.49% | -171.06% | |||
| EPS Diluted | 52.88% | -137.10% | |||
| Normalized Diluted EPS | 69.49% | -171.06% | |||
| Average Basic Shares Outstanding | 0.03% | 20.07% | |||
| Average Diluted Shares Outstanding | 0.03% | 20.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||